Zoetis (ZTS): insider & executive buying
Zoetis · Health Care · ref. ETF XLV · price $75.02
In short — 3 insiders bought Zoetis over ~6 months (3 buys, total $886k, latest May 13, 26) — cluster buy. Public Form 4 data, informative (not a performance signal).
Are Zoetis's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$75.02-51.5% over range
Aug 28, 25low $71.86 · high $156.4Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
50% recommend buying · 12 analysts
Latest insider buys on Zoetis
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| May 13, 26 | Damelio Frank A | Dir | 6,650 | $501k |
| May 13, 26 | Bisaro Paul | Dir | 2,000 | $152k |
| May 11, 26 | McCallister Michael B | Dir | 3,000 | $233k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Zoetis's executives bought shares recently?
3 Zoetis insider(s) bought $886k over ~6 months (latest May 13, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for ZTS?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Zoetis? The JPI assistant answers using our backtest data.